Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

Clinical trial NCT03367299 · COMPLETED

Trial details

NCT number: NCT03367299
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Lymphoid Leukemia Philadelphia Chromosome-Negative B-Cell Precursor

Start date: 2018-06-08
Primary completion: 2024-09-02
Enrollment: 149

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.